Sign in
Enrolling by invitationNo phase

Mapping only slow-conducting heart tissue to guide ablation for ventricular tachycardia

Tests a new ablation mapping approach in adults with ventricular tachycardia.

Key facts

Who runs it
VA Office of Research and Development
Where
San Diego, United StatesSee the site
Trial code
Registry title
Functional Substrate-Only Guided VT Ablation
Status
Enrolling by invitation
People taking part
36 people, planned
Started
18 Mar 2026
Expected to end
1 Apr 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Functional Substrate-Only Mapping without VT Induction
  • Standard-of-Care Mapping/Imaging
Record updated
25 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults sent for a VT ablation, a procedure that destroys the heart tissue causing ventricular tachycardia, a dangerous fast heart rhythm. Their VT must come from scarred heart tissue.

Age
>18 years, up to 90 Years
Sex
Men and women
Disease stage
Monomorphic or polymorphic VT linked to scar tissue in people with structural heart disease. The VT must be recorded by telemetry, ICD check, ECG or event monitor. Structural heart disease is shown by heart scans or ECG findings, or a past heart attack. People having epicardial ablation (on the outer surface of the heart) with preventive heart pump support can also join.
Biomarker or test result
Signs of scarring on tests, for example a nuclear scan defect >5%, late gadolinium uptake on cardiac MRI, wall thinning <10mm or calcified heart muscle on cardiac CT, weak wall movement on echocardiogram, or Q waves on ECG.

Main reasons for not taking part

  • Pregnancy
  • Blood clot inside the heart
  • Active heart blood-flow problem with untreated narrowed arteries (CAD >70% stenosis), or bacteria in the blood
  • Heart chambers that cannot be reached because of two mechanical valves
  • Cannot take blood thinners during ablation and for at least 1 month after

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Men and women >18 years of age referred for clinically indicated VT ablation and experience monomorphic or polymorphic scar-based VT documented by telemetry, ICD interrogation, ECG or event monitoring
  • Scar-based VT is defined as VT in patients with structural heart disease (assessed with either abnormal nuclear perfusion imaging (>5% defect), late gadolinium uptake on cardiac MRI, wall thinning <10mm or calcified myocardium on cardiac CT, akinesis or hypokinesis on echocardiogram, presence of Q waves on ECG, history of myocardial infarct)
  • Patients undergoing epicardial VT ablation and who undergo prophylactic percutaneous hemodynamic support devices will also be included

Who cannot take part

  • Patients without structural heart disease will be excluded from the pri-mary analysis, but enrolled in a prospective registry
  • active acute coronary ischemia with unrevascularized coronary artery disease (CAD >70% stenosis)
  • Patients who are pregnant
  • Presence of intracardiac thrombus
  • Active bacteremia
  • Inaccessible ventricles due to dual mechanical valves
  • Inability to tolerate and inability to tolerate anticoagulation during ablation and for at least 1 month after ablation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

Where in United States

  • VA San Diego Healthcare System, San Diego, CASan Diego, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Ventricular tachycardia (VT) is a leading cause of death and suffering in the Veteran population. Currently, ablation procedures are performed to destroy the diseased tissue that causes this problem. This study will test to see if an experimental strategy of only targeting regions of slow conduction without the induction of VT can improve the efficacy and safety of VT ablation. Once this study is completed, the investigators will know whether this ablation strategy could help increase the efficacy, safety and efficiency of ablation therapy of fatal heart rhythms.

The 2 groups in the trial

  • Functional substrate mapping only without VT inductionTreatment being tested

    In this experimental arm, only functional substrate mapping will be used to guide ablation of conduction slowing regions, without VT induction or mapping during VT. Ablation targets of conduction slowing will be identified as: 1) deceleration zones of conduction slowing, previously defined as 3 isochrones coalescing within 1cm radius. 2) wavefront discontinuities represented by lines of conduction block, previously defined as late potentials with at least 20ms of isoelectric segment, and 3) regions of slow conduction characterized by high peak frequency (220-500Hz), which uses spectral frequency analysis to identify signals with highest frequency as a surrogate for slow conduction. All regions exhibiting any of these 3 surrogates of slow conduction will be ablated.

    Treatment: Functional Substrate-Only Mapping without VT Induction

  • Standard VT MappingExisting treatment, for comparison

    Standard-of-care mapping, including voltage mapping of intrinsic rhythm, entrainment, activation, and/or pace mapping, will be performed to guide VT ablation. Standard VT induction protocols will be performed.

    Treatment: Standard-of-Care Mapping/Imaging

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Functional Substrate-Only Mapping Technique to Guide Ablation of Arrhythmogenic Substrate Underlying Ventricular Tachycardia
Plain-language title
Mapping only slow-conducting heart tissue to guide ablation for ventricular tachycardiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06464315, who can take part
Record updated
25 March 2026